Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


C75, a Fatty Acid Synthase (FAS) Inhibitor

Author(s): Miguel Lopez and Carlos Dieguez

Affiliation: Department of Physiology, School of Medicine, University of Santiago de Compostela, C/ San Francisco s/n 15782, Santiago de Compostela, A Coruna, Spain.

Keywords: AMP-activated protein kinase (AMPK), C75, cerulenin, fatty acid synthase (FAS), FAS inhibitors, food intake, hypothalamus, lipid sensing, tamoxifen


Recent data has demonstrated that fatty acid metabolism plays a critical role in the hypothalamic regulation of food intake and the evidence is as follows. Circulating long chain fatty acids act as nutrient surplus signals in the hypothalamus. On addition, fatty acid synthesis pathway enzymes, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) and its upstream regulator, AMP-activated protein kinase (AMPK) are regulated by nutritional and hormonal stimuli. Very importantly, current evidence also indicates that fatty acid metabolism pathway may be a potential target for obesity treatment. In this sense, it has been demonstrated that pharmacological inhibition of FAS results in profound decrease in food intake and body weight in rodents. These anorectic actions are mediated by the modulation of hypothalamic neuropeptide systems, through a malonyl-CoA dependent mechanism. In this review, we recapitulate what is known about hypothalamic fatty acid metabolism and the regulation of feeding, with particular interest in a specific FAS inhibitor, C75, which has been recently patented as a potential drug for adipose mass reduction.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [53 - 62]
Pages: 10
DOI: 10.2174/187221407779814615